---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-010770"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:02:35.872025+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# PTC Therapeutics Q2 2025: Sephience approved in EU and US; total revenue $179M; net loss narrows

## Summary
- Sephience (sepiapterin) received EC and FDA approval with broad label for PKU across all ages and subtypes; global launch initiated.
- Q2 total revenue $178.9M (vs $186.7M Q2 2024); DMD franchise $96M: Translarna $59.5M, Emflaza $36.4M.
- Net loss improved to $64.8M from $99.2M; cash & securities $1.99B (up from $1.14B at Dec 31, 2024).
- Entered agreement to buy out Censa sales milestone obligation for $225M upfront plus future milestones.
- FY2025 revenue guidance $650-800M; vatiquinone PDUFA date Aug 19, 2025; positive Phase 2 HD results for votoplam.

## SEC filing metadata
- accession: 0001558370-25-010770
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000155837025010770/0001558370-25-010770-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000155837025010770/tmb-20250807x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-010770
- JSON: https://secwatch.observer/filing/0001558370-25-010770.json
- Plain text: https://secwatch.observer/filing/0001558370-25-010770.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.